Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...

Seer’s presence at HUPO 2025 represents one of the most comprehensive demonstrations of its technology to date, with more than a dozen scientific presentations, including two invited talks in the ...

Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER) (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced ...

Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...

Q3 2025 Management View CEO Omid Farokhzad emphasized the company's continued momentum, highlighting "a record number of ...

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be ...

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay ...

Seer will host a conference call to discuss the third quarter 2025 financial results on Thursday, November 6, 2025 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can ...